ClinicalTrials.gg
Active, not recruitingNCT05648968VAYHIAUpdated Sep 11, 2026

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

A Phase 3 interventional study of Ianalumab and Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 53 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Read the detailed description

The primary objective is to demonstrate that either dose of ianalumab induces a durable hemoglobin response compared to placebo in patients with wAIHA.

The key secondary objective is to demonstrate that either dose of ianalumab maintains a durable hemoglobin response that is sustained beyond end of the treatment period, compared to placebo.

Participants are randomized to two different doses of ianalumab or placebo. Participants who were assigned to placebo arm and not responding to treatment may be treated with open label ianalumab using the higher dose.

The investigational treatment will be supplied in a double-blinded manner. For the open label period, ianalumab will be provided in an open label manner.

In addition to the randomized treatment (ianalumab or placebo), specific supportive care medication as defined in the protocol is allowed. If clinically indicated (e.g., to ensure patient safety), the treating physician may also administer rescue medication.

The study consists of the treatment period, efficacy and safety follow-up periods. The visit frequency will be every other week during the treatment and primary endpoint follow up period; for safety monitoring monthly during the first 20 weeks after last dose and afterwards quarterly up to 2 years from the last dose. For participants in durable response, additional visits for efficacy will occur monthly during the first 2 years after the last dose, and afterwards quarterly until loss of response or end of study, latest until up to 39 months post randomization of the last participant.

02

Conditions studied

  • Warm Autoimmune Hemolytic Anemia (wAIHA)

Keywords

  • warm autoimmune hemolytic anemia
  • wAIHA
  • ianalumab
  • VAY736
  • B-cell depletion
  • B-cell Activating Factor Receptor (BAFF-R) blockade
03

In context

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

This study's enrollment of 90 is above the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.

Browse Anemia, Hemolytic, Autoimmune studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 years and older at time of signing consent
  • Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, who had an insufficient response to, or after at least one , including patients with resistance, dependence or intolerance
  • concentration at screening and at Week 1 >=5 g/dL and \<10 g/dL, associated with presence of symptoms related to anemia
  • The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study

Key Exclusion Criteria:

  • wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL) or another immunologic disease requiring prohibited medication as per protocol. Patients with diseases after wash-out from the treatments are allowed.
  • Presence of other forms of AIHA (cold or intermediate forms), Evans Syndrome or other cytopenias
  • Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to randomization, or without hematological response to the last course of B-cell depleting therapy
  • Neutrophils: \<1000/mm3
  • Serum creatinine >1.5 × (ULN)
  • Immunoglobulin G (IgG) \<5g/L
  • Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2) requiring systemic treatment at time of screening, or history of recurrent infection
  • Positivity for virus, surface antigen (HBsAg), or hepatitis B core antibody (HBcAb). HBcAb positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given.
  • Known history of primary or secondary immunodeficiency, or a positive human immune deficiency virus () test result
  • Live or within 4 weeks before randomization
  • History of splenectomy

Other protocol-defined Inclusion/Exclusion may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Ianalumab low dose

    Participants will receive low dose ianalumab intravenously

    Biological: Ianalumab

  • Experimental
    Ianalumab high dose

    Participants will receive high dose ianalumab intravenously

    Biological: Ianalumab

  • Placebo comparator
    Placebo

    Participants will receive placebo intravenously

    Drug: Placebo

Interventions

  • BiologicalIanalumab

    i.v. infusion, prepared from concentrate solution

    Also known as: VAY736

  • DrugPlacebo

    i.v. infusion, prepared from matching placebo

06

What researchers measure

Primary outcomes

  1. Binary variable indicating whether a patient achieves a durable response

    Durable response: hemoglobin level ≥10 g/dL and ≥2 g/dL increase from baseline, for a period of at least eight consecutive weeks between W9 and W25, in the absence of rescue medication or prohibited treatment

    Time frame: Randomization to Week 25

Secondary outcomes

  1. Duration of response (Key Secondary)

    • For patients who previously reached durable response: Time from first hemoglobin assessment showing durable response to confirmed loss of durable response, defined as the first of the following events: * hemoglobin level \<10 g/dL in at least two consecutive weekly assessments, * start of any rescue medication or prohibited treatment, * death; • For patients who did not achieve the durable response according to primary endpoint definition: duration will be 0 days

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  2. Time from randomization to start of durable response in each treatment group

    Durable response is defined as in primary endpoint.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  3. Time from randomization to start of first response in each treatment group

    Response is defined as hemoglobin level of at least 10 g/dL and an increase of at least 2 g/dl from baseline, or normalization of hemoglobin (at least 11 g/dL for women and 12 g/dL for men), without biochemical resolution of hemolysis.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  4. Time from randomization to start of complete response in each treatment group

    Complete response is defined as normalization of hemoglobin levels and no evidence of hemolysis (normal levels of indirect bilirubin, LDH, haptoglobin and reticulocytes), in the absence of red blood cell transfusions.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  5. Response rate

    Assessment of quality of response in each treatment group.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  6. Complete response rate

    Assessment of complete response rate in each treatment group.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  7. Hemoglobine Levels

    Assessment of hemoglobin levels in each treatment group.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  8. Number of participants who received rescue treatment (overall & by type of rescue treatment)

    This is to assess the need for rescue treatment in all treatment groups, measured as time-standardized numbers of each type of rescue treatment and as change from baseline in time-standardized number of transfusions.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  9. Percentage of participants who received rescue treatment (overall & by type of rescue treatment)

    This is to assess the need for rescue treatment in all treatment groups.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  10. Change from baseline in the the frequency and absolute number of CD19+ B cell counts

    Change from baseline in the the frequency and absolute number of CD19+ B cell counts in whole blood

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  11. Time to first occurrence of B cell recovery, defined as ≥80% of baseline or ≥50 cells/μL

    Time to first occurrence of B cell recovery, defined as ≥80% of baseline or ≥50 cells/μL in whole blood

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  12. Change from baseline in immunoglobulin levels

    Change from baseline in immunoglobulin levels (change in titers of IgG, IgM, IgA)

    Time frame: Randomization until month 30

  13. Change from baseline in the 8 domain scores and in the summary scores (PCS, MCS) of SF-36 questionnaire

    SF-36 v2.0 (acute) includes 36 items that assess general health related quality of life covering 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role-emotional health and mental health. Scores for the 8 domains are generated, as well as a physical component summary (PCS) score and a mental component summary (MCS) score. Responses to items are based on a 5-point Likert scale. Scores below 50 indicate less than average health, while scores above 50 indicate better than average health.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  14. Change from baseline in the T-score of PROMIS Fatigue-13a questionnaire

    Assessment of quality of life in each treatment group. The PROMIS Short Form v1.0 Fatigue-13a includes 13 items that assess fatigue. All items in the PROMIS-Fatigue-13a utilize a 5-point response scale (e.g., not at all, a little bit, somewhat, quite a bit, very much). Higher scores on the PROMIS-Fatigue-13a represent greater fatigue.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  15. Ianalumab PK parameter - AUClast

    AUClast: area under the curve from time zero to last measurable concentration sampling time (tlast).

    Time frame: After first dose of study treatment (pre-dose, 2 hours, 336 hours, 672 hours post dose) and after last dose (pre-dose, 2 hours, 336 hours, 672 hours, 1344 hours, 2016 hours and 3360 hours post dose).

  16. Ianalumab PK parameter - AUCtau

    AUCtau: the AUV calculated to the end of a dosing interval (tau).

    Time frame: After first dose of study treatment (pre-dose, 2 hours, 336 hours, 672 hours post dose) and after last dose (pre-dose, 2 hours, 336 hours, 672 hours, 1344 hours, 2016 hours and 3360 hours post dose).

  17. Ianalumab PK parameter - Accumulation ratio Racc

    Accumulation ratio calculated using AUC values obtained between last and first dose

    Time frame: After last dose (pre-dose, 2 hours, 336 hours, 672 hours, 1344 hours, 2016 hours and 3360 hours post dose).

  18. Ianalumab PK parameter - Cmax

    Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

    Time frame: After first dose of study treatment (pre-dose, 2 hours, 336 hours, 672 hours post dose) and after last dose (pre-dose, 2 hours, 336 hours, 672 hours, 1344 hours, 2016 hours and 3360 hours post dose).

  19. Ianalumab PK parameter - Tmax

    Time to reach maximum (peak) plasma, blood, serum or other body fluid drug concentration

    Time frame: After first dose of study treatment (pre-dose, 2 hours, 336 hours, 672 hours post dose) and after last dose (pre-dose, 2 hours, 336 hours, 672 hours, 1344 hours, 2016 hours and 3360 hours post dose).

  20. Immunogenicity of ianalumab

    Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time. Confirmed anti-drug-antibody positive samples will be further characterized for neutralizing capacity.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

07

Study locations

53 sites
  • Michigan Center of Medical Research
    Farmington Hills, Michigan 48334, United States
  • University of Minnesota Med Center
    Minneapolis, Minnesota 55455, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1414DRK, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1039AAC, Argentina
  • Novartis Investigative Site
    Caba, C1015ABO, Argentina
  • Novartis Investigative Site
    Garran, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Dalian, 116000, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Giessen, 35392, Germany
  • Novartis Investigative Site
    Hanover, 30161, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Madurai, Tamil Nadu 625107, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226014, India
  • Novartis Investigative Site
    Kfar Saba, 4428164, Israel
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
  • Novartis Investigative Site
    Milan, MI 20100, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Bassano del Grappa, VI 36061, Italy
  • Novartis Investigative Site
    Novara, 28100, Italy
  • Novartis Investigative Site
    Narita, Chiba 2868523, Japan
  • Novartis Investigative Site
    Matsuyama, Ehime 7900024, Japan
  • Novartis Investigative Site
    Gifu, Gifu 5011194, Japan
  • Novartis Investigative Site
    Kobe, Hyōgo 6500047, Japan
  • Novartis Investigative Site
    Isehara, Kanagawa 2591193, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 1738610, Japan
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 1600023, Japan
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    Johor Bahru, 80100, Malaysia
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 308433, Singapore
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Murcia, 30008, Spain
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Novartis Investigative Site
    Leeds, LS1 3EX, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Feb 2026, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 13, 2022
StartActual
Dec 30, 2022
Primary completionActual
Feb 20, 2026
CompletionEst.
Dec 19, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648968
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Dec 30, 2022
Primary completion
Feb 20, 2026
Completion
Dec 19, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion